Health ❯ Healthcare ❯ Patient Care

Treatment Efficacy

Progression-Free Survival Response Rates Side Effects Adverse Effects Quality of Life Long-term Outcomes Clinical Outcomes Survival Rates Side Effects Management Clinical Trials

4 ARTICLES

3w ago

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Topline phase 1/2 results suggest the MTAP‑deleted, RAS‑mutant combination could enable a precision, chemotherapy‑sparing first‑line approach if randomized trials confirm the finding.

10 ARTICLES

3w ago

Teclistamab Significantly Lengthens Remissions and Survival in Relapsed Myeloma Trial

4 ARTICLES

last mo.

EMA Recommends Jascayd for Two Progressive Lung Fibrosis Conditions

4 ARTICLES

last mo.

Apnimed Pill Cuts Sleep Apnea Events in Phase 3 as Company Seeks FDA Approval

9 ARTICLES

last mo.

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

3 ARTICLES

last mo.

Imfinzi With Enfortumab Vedotin Improves Survival in Phase III Bladder Cancer Trial

3 ARTICLES

last mo.

Novartis Breaks Ground on Texas Plant to Speed Radioligand Cancer Drug Delivery

13 ARTICLES

2mo ago

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

3 ARTICLES

2mo ago

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

3 ARTICLES

2mo ago

First-in-Human SynKIR-110 Shows Safe Profile and Early Activity in Solid Tumors

3 ARTICLES

2mo ago

AI Model Predicts Which Bowel Cancer Patients May Benefit From NHS Drug

16 ARTICLES

2mo ago

Single CAR-T Infusion Puts Three Severe Autoimmune Diseases in Remission

10 ARTICLES

3mo ago

Mexico Tightens Drug-Supply Oversight After Reaching 97% Availability

4 ARTICLES

3mo ago

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

9 ARTICLES

3mo ago

Polilaminina Enters Regulated Testing as Lead Researcher Moves to Correct Preprint

3 ARTICLES

4mo ago

FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis

3 ARTICLES

5mo ago

NICE Endorses Dupilumab as First Targeted Biologic for Uncontrolled Eosinophilic COPD

Treatment Efficacy

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

Praxis Drug Vormatrigine Misses Primary Goal in Phase 2/3 POWER1 Trial

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

Teclistamab Significantly Lengthens Remissions and Survival in Relapsed Myeloma Trial

EMA Recommends Jascayd for Two Progressive Lung Fibrosis Conditions

Apnimed Pill Cuts Sleep Apnea Events in Phase 3 as Company Seeks FDA Approval

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Imfinzi With Enfortumab Vedotin Improves Survival in Phase III Bladder Cancer Trial

Novartis Breaks Ground on Texas Plant to Speed Radioligand Cancer Drug Delivery

Never miss stories about

Treatment Efficacy

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

First-in-Human SynKIR-110 Shows Safe Profile and Early Activity in Solid Tumors

AI Model Predicts Which Bowel Cancer Patients May Benefit From NHS Drug

Single CAR-T Infusion Puts Three Severe Autoimmune Diseases in Remission

Mexico Tightens Drug-Supply Oversight After Reaching 97% Availability

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

Polilaminina Enters Regulated Testing as Lead Researcher Moves to Correct Preprint

FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis

NICE Endorses Dupilumab as First Targeted Biologic for Uncontrolled Eosinophilic COPD

Never miss stories about

Treatment Efficacy